Rest Of Europe HLA Typing for Transplant Market (2025-2030)
The Rest Of Europe HLA Typing for Transplant Market was valued at $4.03 Million in 2025 and projected to reach to $4.53 Million by 2030, representing a compound annual growth rate of 2.4%. Rest Of Europe's HLA typing for transplant market demonstrates stable but modest growth, driven by established healthcare infrastructure and consistent transplant volumes across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe HLA Typing for Transplant Market Trends and Insights
- This modest but steady growth reflects Rest Of Europe's mature healthcare infrastructure and established transplant protocols, where HLA typing remains a critical component of donor-recipient matching.
- Rest Of Europe's market growth is driven by consistent transplant volumes, regulatory compliance requirements, and incremental adoption of advanced typing methodologies across regional transplant centers. The Rest Of Europe market operates within a framework of stringent EU and national transplant regulations, which mandate comprehensive HLA compatibility assessment prior to organ allocation.
- Rest Of Europe's slower growth trajectory compared to global benchmarks reflects market saturation in established transplant programs and limited expansion of new transplant capacity.
- However, Rest Of Europe continues to invest in laboratory automation and next-generation sequencing (NGS) technologies to improve typing accuracy and reduce turnaround times, supporting sustained demand through 2030..
Key Market Statistics
- CAGR (2025-2030) 2.4% CAGR
- Market Size, 2025 ~USD 4.03 Million
- Forecast, 2030 ~USD 4.53 Million
- Country Rest Of Europe
Rest Of Europe HLA Typing for Transplant Market Overview
Steady Market Growth :
Rest Of Europe's HLA typing market is expanding at a CAGR of 2.4%, growing from $4.03 million in 2025 to $4.53 million by 2030, reflecting consistent demand within mature healthcare systems.
Established Transplant Infrastructure :
Rest Of Europe benefits from well-developed transplant protocols and standardized HLA typing procedures, ensuring reliable donor-recipient matching across multiple countries with varying regulatory frameworks.
Below-Global Growth Rate :
At 2.4% CAGR, Rest Of Europe's market growth lags the global average of 6%, indicating market saturation and slower adoption of advanced HLA typing technologies compared to emerging regions.
Critical Clinical Application :
HLA typing remains essential for transplant success in Rest Of Europe, driving consistent utilization despite slower growth, as healthcare providers maintain rigorous compatibility testing standards.
Rest Of Europe HLA Typing for Transplant Market Dynamics
- The 2.4% CAGR reflects a mature market where HLA typing is already deeply integrated into clinical protocols, with limited room for rapid expansion.
- Healthcare providers in Rest Of Europe continue to prioritize donor-recipient compatibility testing, ensuring steady demand for HLA typing services. Future growth will be constrained by market saturation and slower technological adoption compared to global leaders.
- However, opportunities exist through improved testing methodologies, increased transplant awareness campaigns, and potential regulatory harmonization across European nations.
- Investment in next-generation sequencing and molecular HLA typing techniques could unlock incremental growth, though adoption rates are expected to remain conservative given the region's established conventional testing practices..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- Rest Of Europe's HLA typing market is valued at $4.03 million in 2025 and will grow to $4.53 million by 2030 at a 2.4% CAGR.
- Rest Of Europe's market growth is constrained by mature transplant infrastructure and regulatory saturation, resulting in slower expansion than global averages.
- Rest Of Europe is adopting NGS and laboratory automation technologies to enhance typing precision and operational efficiency across transplant centers.
- Rest Of Europe's regulatory environment mandates comprehensive HLA compatibility assessment, ensuring consistent baseline demand for typing services through 2030.
HLA Typing for Transplant Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INDEPENDENT REFERENCE LABORATORIES (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 1.05 (2025) |
| Revenue Forecast (Billions) | ~USD 1.4 (2030) |
| Segments Covered | Product & Service, Technology, Type, Application, Transplant Type, End User |
Rest Of Europe HLA Typing for Transplant Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Technology
- Molecular Assays
- Non-Molecular Assays
By Type
- Antibody Screening
- Chimerism Monitoring
- Next-Generation Sequencing
- Other Diagnostic Applications
- Other Pcr-Based Molecular Assays
- Other Sequencing-Based Molecular Assays
- Pcr-Based Molecular Assays
- Real-Time Pcr
- Sanger Sequencing
- Sequence-Specific Oligonucleotide-Pcr
- Sequence-Specific Primer-Pcr
- Sequencing-Based Molecular Assays
By Application
- Diagnostic Applications
- Research Applications
By Transplant Type
- Soft-Tissue Transplants
- Solid Organ Transplants
- Stem Cell Transplants
By End User
- Hospitals & Transplant Centers
- Independent Reference Laboratories
- Research Laboratories & Academic Institutes
Target Audience
- Diagnostic Laboratory Operators : Need market sizing and growth forecasts for Rest Of Europe to plan HLA typing service expansion, optimize testing capacity, and identify underserved secondary markets within the region.
- Medical Device & Reagent Manufacturers : Require regional demand analysis to develop targeted product strategies for Rest Of Europe's mature transplant centers, including adoption rates for advanced HLA typing technologies.
- Healthcare System Administrators : Seek budget planning data and market trends for Rest Of Europe to allocate resources for transplant programs, justify HLA typing infrastructure investments, and benchmark against regional peers.
- Transplant Center Directors : Need competitive intelligence on Rest Of Europe's HLA typing landscape to optimize donor-recipient matching protocols, evaluate technology upgrades, and improve transplant outcomes.
- Market Entry & Business Development Teams : Require detailed Rest Of Europe market analysis to assess expansion opportunities, identify growth drivers, and develop go-to-market strategies for HLA typing solutions in secondary European markets.
Key Companies in the Rest Of Europe HLA Typing for Transplant Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Instruments,Reagents,Software, |
| QUIDEL CORPORATION | United States | Public Company | Instruments (Transfusion & Molecular Platforms used in HLA/compatibility workflows),Reagents & Consumables (Antibody Screening, Donor Typing, Molecular Assays),Software & Informatics, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing,Sanger-based HLA typing, |
| ILLUMINA, INC. | United States | Public Company | NGS instruments,NGS reagents and consumables,Software and DRAGEN-based analysis, |
| QIAGEN | Netherlands | Public Company | Reagents & Assays (PCR, NGS, Sanger HLA, immune response),Instruments (PCR, NGS, sample prep, QC),Software & Bioinformatics (HLA typing, chimerism, data analysis), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Instruments (PCR, real-time, supporting platforms),Reagents & consumables for HLA typing and chimerism,Software & informatics for transplant workflows, |
| CAREDX, INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing (AlloSeq Tx and related),Sanger-based HLA typing, |
| DIASORIN S.P.A. | Italy | Public Company | Reagents and assays (HLA-related and transplant-adjacent),Instruments and platforms (LIAISON, Simplexa, xMAP-based systems),Software and informatics for transplant workflows, |
| BECTON, DICKINSON AND COMPANY | United States | ||
| EUROBIO SCIENTIFIC | France | Public Company | Reagents (PCR, NGS, Sanger),Software (HLA typing, data analysis),Instruments and related hardware, |
KINDRED HEALTHCARE INC.
Kindred Healthcare Inc. is a large private healthcare services company founded in 1985 in the United States, employing 64,200 people. The company operates across multiple healthcare service segments.
QUIDEL CORPORATION
Quidel Corporation is a publicly traded diagnostic company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic testing solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large publicly traded life sciences company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded genomics company founded in 1998 in the United States with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN
QIAGEN is a publicly traded molecular diagnostics company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample and assay technologies for molecular testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded life sciences company founded in 1952 in the United States with 7,450 employees. The company manufactures and distributes clinical diagnostic products and laboratory reagents.
CAREDX, INC.
CareDx, Inc. is a publicly traded molecular diagnostics company founded in 1998 in the United States with 763 employees. The company specializes in transplant diagnostics and precision medicine solutions.
DIASORIN S.P.A.
DiaSorin S.p.A. is a publicly traded Italian diagnostics company founded in 1968 with 3,242 employees. The company specializes in immunodiagnostic and molecular diagnostic products.
BECTON, DICKINSON AND COMPANY
Insufficient data provided for company description.
EUROBIO SCIENTIFIC
Eurobio Scientific is a publicly traded French diagnostics company founded in 1997 with 343 employees. The company develops and distributes in vitro diagnostic products.
Reasons to Buy this Report
- Regional Market Specificity : Gain precise insights into Rest Of Europe's HLA typing market dynamics, excluding major European markets, enabling targeted business strategies for secondary European countries and emerging transplant centers.
- Growth Trajectory Analysis : Understand why Rest Of Europe's 2.4% CAGR differs from global 6% growth, identifying market maturity factors and competitive pressures specific to the region's healthcare landscape.
- Investment Decision Support : Make informed capital allocation decisions for Rest Of Europe expansion, with clear market sizing ($4.03M-$4.53M) and growth forecasts to justify market entry or portfolio adjustments.
- Competitive Positioning : Benchmark your HLA typing solutions against Rest Of Europe's established protocols and healthcare standards, identifying gaps and opportunities for differentiation in a mature market.
- Regulatory & Clinical Insights : Navigate Rest Of Europe's diverse regulatory environments and transplant protocols with region-specific intelligence on compliance requirements and clinical adoption barriers.
Frequently asked questions
What is the current market size of HLA typing for transplant in Rest Of Europe?
Rest Of Europe's HLA typing for transplant market is valued at $4.03 million in 2025.
What is the projected market size for Rest Of Europe by 2030?
Rest Of Europe's HLA typing market is forecast to reach $4.53 million by 2030.
What is the CAGR for Rest Of Europe's HLA typing market?
Rest Of Europe's HLA typing market is expected to grow at a compound annual growth rate of 2.4% from 2025 to 2030.
Why is Rest Of Europe's growth rate lower than the global average?
Rest Of Europe's slower growth reflects market maturity, established transplant infrastructure, regulatory saturation, and limited expansion of new transplant capacity compared to emerging markets.
What technologies are driving growth in Rest Of Europe's HLA typing market?
Rest Of Europe's market growth is supported by adoption of next-generation sequencing (NGS), laboratory automation, and enhanced typing methodologies that improve accuracy and reduce turnaround times.
RESEARCH METHODOLOGY
This study analyzed market variables related to small and medium-sized businesses and major corporations to balance primary and secondary research for the human leukocyte antigen (HLA) typing for transplant market. The next phase involved conducting primary research with industry experts along the value chain to validate the findings, assumptions, and market sizing. Several methodologies were employed to estimate the overall market size, including both top-down and bottom-up approaches. This study focuses on key market segments, emerging trends, regulatory frameworks, and competitive environments. It also examines leading market players and their strategies within this sector. In conclusion, the total market size was determined using top-down and bottom-up approaches and data triangulation to arrive at the final figure. Ongoing primary research was conducted throughout the study to validate and test each hypothesis.
Secondary Research
During the study, secondary research utilized a variety of sources, including directories and databases such as Bloomberg Businessweek, D&B Hoovers, and Factiva. Additional materials included white papers, annual reports, SEC filings, and investor presentations. This research approach collects and generates data that offers comprehensive, technical, and market-focused insights into the HLA typing for transplant market. The data provides information on key players and market segmentation based on recent industry trends and significant market developments. Additionally, a database of leading industry figures was created through this secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the HLA typing for transplant market. The primary sources from the demand side include medical OEMs, CDMOs, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*Others include distributors, suppliers, product managers, business development managers, marketing managers, and sales managers.
Note: Companies are categorized into tiers based on their total revenue. As of 2024, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global HLA typing for transplant market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA typing for transplants business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players/OEMs operating in the HLA typing for transplant market
- Mapping the annual revenue generated by major global players from the HLA typing segment (or the nearest reported business unit/product category)
- Revenue mapping of top players to cover at least ~75% of the global market share as of 2024
- Extrapolation of the revenue mapping of major players to derive the global value of the market
- Extrapolating the global value of the HLA typing for transplant market.
- Summation of market value for all segments and subsegments to achieve the actual value of the global HLA typing for transplant market
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global HLA typing for transplant market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, top-down and bottom-up approaches validated the HLA typing for transplant market.
Market Definition
HLA typing assays are critical in transplant immunology, as they facilitate the identification of HLA antigens essential for assessing donor-recipient compatibility and mitigating the risk of alloimmune rejection. These assays are pivotal in donor-recipient cross-matching, subject profiling, genotyping, and various diagnostic applications. Recent advancements in HLA typing technology, which enable high-resolution typing, afford precise delineation of HLA allele variations. This increased accuracy significantly enhances the predictive capability for transplant outcomes, thereby minimizing rejection and graft-versus-host disease incidence. As a result, these innovations are instrumental in making transplantation a more feasible and successful therapeutic option for patients.
Stakeholders
- Manufacturers of HLA typing products for transplant
- Distributors & suppliers of HLA typing products for transplant
- Hospitals, Transplant Centers, reference laboratories, Cord Blood Banks
- Research Laboratories and Academic Institutes
- Organ Procurement Organizations (OPOs)
- Non-government organizations
- Government regulatory authorities
- Contract manufacturers and third-party suppliers
- Clinical research organizations (CROs)
- Government and non-governmental regulatory authorities
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the HLA typing for transplant market based on product & service, technology, application, transplant type, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing for transplant market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global HLA typing for transplant market
- To provide an average selling price trend for the target product categories in HLA typing for transplant market
- To analyze key growth opportunities in the global HLA typing for transplant market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), the Asia Pacific (Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key players in the global HLA typing for transplant market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global HLA typing for transplant market, such as product launches, agreements, expansions, and acquisitions
Get the Full HLA Typing for Transplant Market Report
Full forecast, segment splits, and company analysis for all HLA Typing for Transplant Market.
- US HLA Typing for Transplant Market
- Canada HLA Typing for Transplant Market
- Germany HLA Typing for Transplant Market
- UK HLA Typing for Transplant Market
- France HLA Typing for Transplant Market
- Spain HLA Typing for Transplant Market
- Italy HLA Typing for Transplant Market
- China HLA Typing for Transplant Market
- India HLA Typing for Transplant Market
- Japan HLA Typing for Transplant Market
- Australia HLA Typing for Transplant Market
- South Korea HLA Typing for Transplant Market
- Brazil HLA Typing for Transplant Market
- Mexico HLA Typing for Transplant Market
- Rest Of Asia Pacific HLA Typing for Transplant Market
- Rest Of Latin America HLA Typing for Transplant Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
